<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
        {font-family:Wingdings;
        panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
        {font-family:"Cambria Math";
        panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
        {font-family:Calibri;
        panose-1:2 15 5 2 2 2 4 3 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
        {margin:0in;
        font-size:11.0pt;
        font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
        {mso-style-priority:99;
        color:#0563C1;
        text-decoration:underline;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
        {mso-style-priority:34;
        margin-top:0in;
        margin-right:0in;
        margin-bottom:0in;
        margin-left:.5in;
        font-size:11.0pt;
        font-family:"Calibri",sans-serif;}
span.EmailStyle17
        {mso-style-type:personal-compose;
        font-family:"Calibri",sans-serif;
        color:windowtext;}
.MsoChpDefault
        {mso-style-type:export-only;}
@page WordSection1
        {size:8.5in 11.0in;
        margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
        {page:WordSection1;}
/* List Definitions */
@list l0
        {mso-list-id:736977858;
        mso-list-type:hybrid;
        mso-list-template-ids:-932260374 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l0:level1
        {mso-level-number-format:bullet;
        mso-level-text:\F0B7;
        mso-level-tab-stop:none;
        mso-level-number-position:left;
        text-indent:-.25in;
        font-family:Symbol;}
@list l0:level2
        {mso-level-number-format:bullet;
        mso-level-text:o;
        mso-level-tab-stop:none;
        mso-level-number-position:left;
        text-indent:-.25in;
        font-family:"Courier New";}
@list l0:level3
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:none;
        mso-level-number-position:left;
        text-indent:-.25in;
        font-family:Wingdings;}
@list l0:level4
        {mso-level-number-format:bullet;
        mso-level-text:\F0B7;
        mso-level-tab-stop:none;
        mso-level-number-position:left;
        text-indent:-.25in;
        font-family:Symbol;}
@list l0:level5
        {mso-level-number-format:bullet;
        mso-level-text:o;
        mso-level-tab-stop:none;
        mso-level-number-position:left;
        text-indent:-.25in;
        font-family:"Courier New";}
@list l0:level6
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:none;
        mso-level-number-position:left;
        text-indent:-.25in;
        font-family:Wingdings;}
@list l0:level7
        {mso-level-number-format:bullet;
        mso-level-text:\F0B7;
        mso-level-tab-stop:none;
        mso-level-number-position:left;
        text-indent:-.25in;
        font-family:Symbol;}
@list l0:level8
        {mso-level-number-format:bullet;
        mso-level-text:o;
        mso-level-tab-stop:none;
        mso-level-number-position:left;
        text-indent:-.25in;
        font-family:"Courier New";}
@list l0:level9
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:none;
        mso-level-number-position:left;
        text-indent:-.25in;
        font-family:Wingdings;}
@list l1
        {mso-list-id:825515986;
        mso-list-type:hybrid;
        mso-list-template-ids:-2066163538 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l1:level1
        {mso-level-number-format:bullet;
        mso-level-text:\F0B7;
        mso-level-tab-stop:none;
        mso-level-number-position:left;
        text-indent:-.25in;
        font-family:Symbol;}
@list l1:level2
        {mso-level-number-format:bullet;
        mso-level-text:o;
        mso-level-tab-stop:none;
        mso-level-number-position:left;
        text-indent:-.25in;
        font-family:"Courier New";}
@list l1:level3
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:none;
        mso-level-number-position:left;
        text-indent:-.25in;
        font-family:Wingdings;}
@list l1:level4
        {mso-level-number-format:bullet;
        mso-level-text:\F0B7;
        mso-level-tab-stop:none;
        mso-level-number-position:left;
        text-indent:-.25in;
        font-family:Symbol;}
@list l1:level5
        {mso-level-number-format:bullet;
        mso-level-text:o;
        mso-level-tab-stop:none;
        mso-level-number-position:left;
        text-indent:-.25in;
        font-family:"Courier New";}
@list l1:level6
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:none;
        mso-level-number-position:left;
        text-indent:-.25in;
        font-family:Wingdings;}
@list l1:level7
        {mso-level-number-format:bullet;
        mso-level-text:\F0B7;
        mso-level-tab-stop:none;
        mso-level-number-position:left;
        text-indent:-.25in;
        font-family:Symbol;}
@list l1:level8
        {mso-level-number-format:bullet;
        mso-level-text:o;
        mso-level-tab-stop:none;
        mso-level-number-position:left;
        text-indent:-.25in;
        font-family:"Courier New";}
@list l1:level9
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:none;
        mso-level-number-position:left;
        text-indent:-.25in;
        font-family:Wingdings;}
ol
        {margin-bottom:0in;}
ul
        {margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72" style="word-wrap:break-word">
<div class="WordSection1">
<p class="MsoNormal">All,<o:p></o:p></p>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal">Please join us on Wednesday, April 27, 2022 at 9:00am (PDT),  12:00pm (EDT), 6:00pm (CEST) for a webinar by Yang Shi and Sofia Lovestam (MRC-LMB) and Abhay Kotecha (Thermo Fisher).  They will present recently published results in Nature
 and Elife,  “<em><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#333333">Tale of amyloid filaments in neurodegenerative diseases”</span></em><em><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#333333;font-style:normal">. 
<o:p></o:p></span></em></p>
<p class="MsoNormal"><em><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#333333;font-style:normal"><o:p> </o:p></span></em></p>
<p class="MsoNormal"><em><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#333333;font-style:normal">Webinar will be able to watch on-demand, but registration is required.  </span></em><em><span style="font-size:10.0pt;font-family:"Arial",sans-serif;font-style:normal"><o:p></o:p></span></em></p>
<p class="MsoNormal"><em><span style="font-size:10.0pt;font-family:"Arial",sans-serif;font-style:normal">Register on Labroots.com:
<a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.labroots.com_ms_webinar_tale-2Damyloid-2Dfilaments-2Dneurodegenerative-2Ddiseases&d=DwMFAg&c=-35OiAkTchMrZOngvJPOeA&r=L7-zyQ-04fFCMRqzLIOnx7H0exGZHwIQe_wMPuY600I&m=06rwEJ-difwj_zzMlEehq7sBjJeFlWAlNZIHPQynfvmrbFbMyS8Sl1Mvnl8gPCq8&s=EpA1fzOo4yuIwo1eDz9Wnr0vi8I_5IvQ7HrV-j8QeBA&e=">
https://www.labroots.com/ms/webinar/tale-amyloid-filaments-neurodegenerative-diseases</a><o:p></o:p></span></em></p>
<p class="MsoNormal"><em><span style="font-size:10.0pt;font-family:"Arial",sans-serif;font-style:normal"><o:p> </o:p></span></em></p>
<p class="MsoNormal"><b>Abstract<o:p></o:p></b></p>
<p class="MsoNormal" style="text-indent:.5in">Abnormal accumulation of misfolded tau protein in filaments characterizes more than 20 neurodegenerative diseases—collectively called tauopathies. Most of these diseases can be attributed to mutations in tau gene.
 Cryo-electron microscopy (cryo-EM) has been used to solve the structures of tau filaments extracted from diseased brain tissue of neuropathologically confirmed cases of Alzheimer's disease, primary age-related tauopathy (PART), chronic traumatic encephalopathy
 (CTE), Pick's disease, and corticobasal degeneration (CBD). This study led to over 40 high resolution structures of tau filaments found in all these different tauopathies. On top of the previously studied diseases, we have also determined the structures of
 tau filaments from a further eight tauopathies including progressive supranuclear palsy (PSP) and argyrophilic grain disease (AGD). These cryo-EM findings suggest a hierarchical classification of tauopathies on the basis of their filament folds, which complements
 clinical diagnosis and neuropathology and also allows the identification of new tauopathies.<o:p></o:p></p>
<p class="MsoNormal" style="text-indent:.5in">Different diseases are distinguished by different tau folds. To understand the relevance of these folds we require better model systems which can recapitulate this in vitro. This study led to the high-resolution
 structure determination 76 structures of recombinant tau filaments assembled in vitro, providing a new database for the greater amyloid field. Understanding their molecular mechanism holds important implications for future diagnostic and treatment approaches.<o:p></o:p></p>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal"><b>Learning Objectives<o:p></o:p></b></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoListParagraph" style="margin-left:0in;mso-list:l0 level1 lfo3">Review amyloid filaments and neurodegenerative diseases<o:p></o:p></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l0 level1 lfo3">Define what are taupathies and how are they related to neurodegenerative diseases<o:p></o:p></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l0 level1 lfo3">Describe how high throughput cryo-EM can help identify new tauopathies<o:p></o:p></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l0 level1 lfo3">Relate future opportunities and how these structures can be used for Pharma intervention<o:p></o:p></li></ul>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal" style="background:white"><b><span style="font-size:9.0pt;font-family:"Arial",sans-serif;color:#555759;background:white">Leah Lavery, PhD</span></b><span lang="EN-GB"><o:p></o:p></span></p>
<p class="MsoNormal" style="background:white"><span style="font-size:9.0pt;font-family:"Arial",sans-serif;color:#555759;background:white">Sr. Marketing Development Manager, Thermo Fisher Scientific</span><span lang="EN-GB"><o:p></o:p></span></p>
<p class="MsoNormal" style="background:white"><u><span style="font-size:9.0pt;font-family:"Arial",sans-serif;color:#0563C1;background:white"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__thermofisher.com_selectris&d=DwMFAg&c=-35OiAkTchMrZOngvJPOeA&r=L7-zyQ-04fFCMRqzLIOnx7H0exGZHwIQe_wMPuY600I&m=06rwEJ-difwj_zzMlEehq7sBjJeFlWAlNZIHPQynfvmrbFbMyS8Sl1Mvnl8gPCq8&s=MkQph2RToQvPj-jyAfQNLuH6gCM6v_8P7JlgE6LEA-k&e=">https://thermofisher.com/selectris</a></span></u><span lang="EN-GB"><o:p></o:p></span></p>
<p class="MsoNormal" style="background:white"><span style="color:black;background:white"> </span><span lang="EN-GB"><o:p></o:p></span></p>
<p class="MsoNormal"><o:p> </o:p></p>
</div>
</body>
</html>